Drugs / OR2805
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05094804 | Sep 2021 → Apr 2024 | head and neck squamous cell carcinoma, leiomyosarcoma, liposarcoma, melanoma +2 | OncoResponse, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OR2805 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05094804 ↗ |
| Modality | Monoclonal antibody | “OR2805, a Monoclonal Antibody Targeting CD163” NCT05094804 ↗ |
| Route | Intravenous | “OR2805 by IV administration” NCT05094804 ↗ |